
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics is a clinical-stage biopharmaceutical company with a strong potential for success in the treatment of central nervous system disorders. The company's discovery platform, led by renowned leaders in psychiatry and neuroscience research, utilizes a novel approach to target specific neural circuits linked to disease, resulting in improved efficacy, safety, tolerability, and ease of use. MapLight's initial product candidate, ML-007C-MA, has shown a favorable safety profile in Phase 1 trials and holds promise as a treatment for schizophrenia and Alzheimer's disease psychosis, with the potential for success well above the $2B level if multiple endpoints are met in the ongoing Phase 2 trials.
Bears say
MapLight Therapeutics is facing several fundamental challenges which are likely to impact its stock price in the near future. These include concerns over the company's product candidate, ML-007C-MA, as well as the potential for competition in the neuropsychiatry market. Additionally, the company's financials project a widening net loss and significant R&D spending in the coming years, which may also weigh down its stock. Overall, these factors indicate a negative outlook for MapLight Therapeutics' stock in the short and medium term.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares